174 related articles for article (PubMed ID: 15208622)
21. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Hornreich G; Beller U; Lavie O; Renbaum P; Cohen Y; Levy-Lahad E
Gynecol Oncol; 1999 Nov; 75(2):300-4. PubMed ID: 10525392
[TBL] [Abstract][Full Text] [Related]
22. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Varughese J; Cocco E; Bellone S; de Leon M; Bellone M; Todeschini P; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2011 Jul; 117(14):3163-72. PubMed ID: 21246534
[TBL] [Abstract][Full Text] [Related]
23. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.
Bellone M; Cocco E; Varughese J; Bellone S; Todeschini P; El-Sahwi K; Carrara L; Guzzo F; Schwartz PE; Rutherford TJ; Pecorelli S; Marshall DJ; Santin AD
Int J Gynecol Cancer; 2011 Aug; 21(6):1084-90. PubMed ID: 21633302
[TBL] [Abstract][Full Text] [Related]
24. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
25. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
26. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
[TBL] [Abstract][Full Text] [Related]
27. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
Vathipadiekal V; Saxena D; Mok SC; Hauschka PV; Ozbun L; Birrer MJ
PLoS One; 2012; 7(1):e29079. PubMed ID: 22272227
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC).
Younes G; Segev Y; Begal J; Auslender R; Goldberg Y; Amit A; Lavie O
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():16-20. PubMed ID: 26894377
[TBL] [Abstract][Full Text] [Related]
29. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
30. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
Bellone S; Watts K; Cane' S; Palmieri M; Cannon MJ; Burnett A; Roman JJ; Pecorelli S; Santin AD
Gynecol Oncol; 2005 Jul; 98(1):92-8. PubMed ID: 15904949
[TBL] [Abstract][Full Text] [Related]
31. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
33. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Int J Gynecol Cancer; 2001; 11(5):403-8. PubMed ID: 11737473
[TBL] [Abstract][Full Text] [Related]
34. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Karlan BY; Baldwin RL; Lopez-Luevanos E; Raffel LJ; Barbuto D; Narod S; Platt LD
Am J Obstet Gynecol; 1999 Apr; 180(4):917-28. PubMed ID: 10203660
[TBL] [Abstract][Full Text] [Related]
37. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ
Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173
[TBL] [Abstract][Full Text] [Related]
38. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Lavie O; Ben-Arie A; Pilip A; Rennert G; Cohen Y; Feiner B; Auslnader R
Gynecol Oncol; 2005 Nov; 99(2):486-8. PubMed ID: 16051327
[TBL] [Abstract][Full Text] [Related]
39. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
40. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]